Arcutis Biotherapeutics has spent the weeks since the FDA approval of its topical plaque psoriasis cream Zoryve strengthening its cash position, drawing down $125 million from its loan facility and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback